BioSpace News Archive

Medidata and its customers gain access to pre-configured, pre-approved questionnaires in multiple languages to support clinical study start-up, quality, and efficiency

Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton, reported financial results for the third quarter ended September 30, 2020 and provided recent business highlights.

Taiho Pharmaceutical Co., Ltd, and Lung Therapeutics, Inc. announced an exclusive license agreement of LTI-01, a recombinant human single-chain urokinase plasminogen activator, currently under development by Lung Tx for loculated pleural effusions, for the territory of Japan.

AlzeCure Pharma AB announced that the company has received approval from the regulatory authorities in Sweden to initiate a clinical Phase I study with the drug candidate ACD856.

Patient enrollment in Phase 1/2 studies of EOS-850 A2AR antagonist and EOS-448 FCγR-enabled anti-TIGIT antibody continues with initial data expected in 1H21

BioCryst Pharmaceuticals, Inc. announced that preclinical data on BCX9930, an oral Factor D inhibitor, will be presented at the 62nd American Society of Hematology Annual Meeting being held as a virtual event, December 5-8, 2020.

Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, announced that Craig Parker, president and chief executive officer of Surrozen, will be presenting at the Stifel 2020 Virtual Healthcare Conference.

Complete NDA submission for BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorders on track for Q1 2021

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) dise

- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalc